Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | STAT6 | P42226 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4977865 | 0.90 | SLC29A1 (0.60) | SLC29A1ADORA3TSHRLMNATP53 | |
| SCHEMBL4986535 | 0.86 | SLC29A1 (0.61) | SLC29A1ADORA3ADORA1TSHRADORA2A | |
| SCHEMBL24021943 | 0.85 | SLC29A1 (0.65) | SLC29A1ADORA3ADORA1TSHRADORA2A | |
| SCHEMBL7737737 | 0.84 | ADORA3 (0.67) | SLC29A1ADORA3ADORA1ADORA2A | |
| SCHEMBL7737742 | 0.84 | ADORA3 (0.67) | SLC29A1ADORA3ADORA1ADORA2A | |
| SCHEMBL23982263 | 0.84 | ADORA3 (0.67) | SLC29A1ADORA3ADORA1ADORA2A | |
| SCHEMBL11038083 | 0.84 | SLC29A1 (0.69) | SLC29A1ADORA3ADORA1ADORA2A | |
| SCHEMBL11213486 | 0.84 | SLC29A1 (0.69) | SLC29A1ADORA3ADORA1ADORA2A | |
| SCHEMBL4977887 | 0.84 | SLC29A1 (0.59) | SLC29A1ADORA1ADORA2A | |
| SCHEMBL14262987 | 0.84 | SLC29A1 (0.58) | SLC29A1ADORA3ADORA1TSHRADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070859-A1 | Compounds resistant to metabolic deactivation and methods of use | KANE ROBERT R | 2008-03-20 | — | — | US | disclosed |
| EP-1581547-A2 | COMPOUNDS RESISTANT TO METABOLIC DEACTIVATION AND METHODS OF USE | BAYLOR UNIVERSITY (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004050678-A2 | COMPOUNDS RESISTANT TO METABOLIC DEACTIVATION AND METHODS OF USE | BAYLOR UNIVERSITY (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070859-A1 | Compounds resistant to metabolic deactivation and methods of use | NAT1, NNMT, PNP | SLC29A1 196/4885ADORA3 571/4885ADORA1 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.